244 related articles for article (PubMed ID: 20674669)
1. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.
Curtis JR; Jain A; Askling J; Bridges SL; Carmona L; Dixon W; Finckh A; Hyrich K; Greenberg JD; Kremer J; Listing J; Michaud K; Mikuls T; Shadick N; Solomon DH; Weinblatt ME; Wolfe F; Zink A
Semin Arthritis Rheum; 2010 Aug; 40(1):2-14.e1. PubMed ID: 20674669
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
[TBL] [Abstract][Full Text] [Related]
3. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
Michaud K; Berglind N; Franzén S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Nyberg F; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Askling J
Ann Rheum Dis; 2016 Oct; 75(10):1797-805. PubMed ID: 26857699
[TBL] [Abstract][Full Text] [Related]
4. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.
Vashisht P; Sayles H; Cannella AC; Mikuls TR; Michaud K
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1478-88. PubMed ID: 26866293
[TBL] [Abstract][Full Text] [Related]
5. "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients".
Pappas DA; Kremer JM; Reed G; Greenberg JD; Curtis JR
BMC Musculoskelet Disord; 2014 Apr; 15():113. PubMed ID: 24690143
[TBL] [Abstract][Full Text] [Related]
6. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis registries in Sweden.
van Vollenhoven RF; Askling J
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S195-200. PubMed ID: 16273807
[TBL] [Abstract][Full Text] [Related]
8. The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs.
Pombo-Suarez M; Gomez-Reino J
Pharmacol Res; 2019 Oct; 148():104410. PubMed ID: 31461667
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
Kievit W; Fransen J; Oerlemans AJ; Kuper HH; van der Laar MA; de Rooij DJ; De Gendt CM; Ronday KH; Jansen TL; van Oijen PC; Brus HL; Adang EM; van Riel PL
Ann Rheum Dis; 2007 Nov; 66(11):1473-8. PubMed ID: 17426065
[TBL] [Abstract][Full Text] [Related]
10. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
11. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
12. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
[TBL] [Abstract][Full Text] [Related]
14. A paradigm shift in studies based on rheumatoid arthritis clinical registries.
Cho SK; Sung YK
Korean J Intern Med; 2019 Sep; 34(5):974-981. PubMed ID: 30759964
[TBL] [Abstract][Full Text] [Related]
15. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Iannone F; Zavada J; Morel J; Gottenberg JE; Hyrich KL; Listing J
Ann Rheum Dis; 2017 Feb; 76(2):386-391. PubMed ID: 27307502
[TBL] [Abstract][Full Text] [Related]
16. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Clark W; Jobanputra P; Barton P; Burls A
Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
[TBL] [Abstract][Full Text] [Related]
17. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
Nasir A; Greenberg JD
Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
[TBL] [Abstract][Full Text] [Related]
18. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.
Verstappen SM; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Holmqvist M; Horne L; Lampl K; Michaud K; Nyberg F; Pappas DA; Reed G; Symmons DP; Tanaka E; Tran TN; Yamanaka H; Ho M
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1637-45. PubMed ID: 26201948
[TBL] [Abstract][Full Text] [Related]
19. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Nyberg F; Askling J; Berglind N; Franzén S; Ho M; Holmqvist M; Horne L; Lampl K; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Greenberg JD
Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1121-32. PubMed ID: 26303866
[TBL] [Abstract][Full Text] [Related]
20. Design characteristics of the Corrona Japan rheumatoid arthritis registry.
Yamanaka H; Kishimoto M; Pappas DA; Greenberg JD; Kremer JM; Tanaka Y
Mod Rheumatol; 2018 Jan; 28(1):95-100. PubMed ID: 28448195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
